Uma Borate, Acute Leukemia Translation Lead, Assistant Professor at OHSU (Oregon Health and Science University), shared a post on X:
“Last but not least – Paradigm study establishing Aza-Ven therapy for int/high risk fit transplant eligible AML patients, ct induction chemo. ASH kudos to Dr. Fathi and the study team. Honored to represent Ohio State Hematology with Dr. Mims in this effort. EFS is better with Aza-Ven with inc OR, CRR, but not OS. Also has improved QOL. Will it change your practice?”
More posts featuring Uma Borate.
